Elite in Hemorrhagic Proctocolitis

Marina Aloi

Milan, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Hemorrhagic Proctocolitis
Milan, IT 
OverviewLocationsClinical Research

Overview

Marina Aloi practices in Milan, Italy. Ms. Aloi is rated as an Elite expert by MediFind in the treatment of Hemorrhagic Proctocolitis. Her top areas of expertise are Viral Gastroenteritis, Colitis, Crohn's Disease, Endoscopy, and Colonoscopy.

Her clinical research consists of co-authoring 152 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 53 articles and participated in 3 clinical trials in the study of Hemorrhagic Proctocolitis.

Gender
Female

Locations

Milan, Italy
Other Locations
Rome, Italy
Sapienza, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease
A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial
Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Drug
Study Drugs: Vancomycin, Amoxycillin, Doxycyline, Ciprofloxacin, Methylprednisolone, Metronidazole
Study Phase: Not Applicable
View 3 Less Clinical Trials

152 Total Publications

Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.
Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.
Journal: Journal of Crohn's & colitis
Published: September 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aloi's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile